NEW DELHI: Serum Institute of India CEO Adar Poonawalla Tuesday said the company plans to launch its internally developed vaccine to treat cervical cancer in women later this year. The Drugs Controller General of India (DCGI) granted market clearance to the Serum Institute of India (SII) on Tuesday to produce India’s first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer.
In response to the drug regulator’s approval, Poonawalla tweeted: “For the first time there will be an Indian HPV vaccine for the treatment of cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and thank the #DCGI @MoHFW_INDIA for granting approval today. ”
The drug regulator’s approval of the IBS cancer vaccine followed the recommendation of the Committee of experts on the subject (SEC) on CDSCO’s COVID-19 on June 15.
The company had applied to DCGI seeking marketing authorization for qHPV after completion of the Phase 2/3 clinical trial with the support of the Department of Biotechnology.
Cervical cancer in India is the second most common cancer among women aged 15 to 44.